On-Demand CME Videos
Ask the Experts About Scalp Psoriasis: New Players in an Old Game
About
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 2, 2024
June 3, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
List targeted therapies evaluated specifically for management of moderate-to-severe scalp psoriasis
Discuss the evidence supporting the use of targeted therapies for managing scalp psoriasis in routine practice
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer
Grant/Research Support: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Takeda, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.